Analysts were overly optimistic on Zevra Therapeutics (NASDAQ: ZVRA) as it underperformed in Q3. Despite revenue growth predictions for 2025, ongoing losses affect valuation. Forecasts indicate the company is expected to outperform the industry in growth.